Aquestive Therapeutics, Inc. operates with distinct oral film delivery technology and an innovative epinephrine prodrug platform but struggles with expanding operating losses and regulatory setbacks. The company’s revenue base is anchored by licensed products it manufactures exclusively, while its pipeline projects like Anaphylm™ face significant FDA challenges. Liquidity constraints are pressing, with increasing debt servicing requirements starting mid-2026 that could hinder growth prospects unless refinanced. Investors should monitor FDA review outcomes for pipeline assets and the company’s ability to secure capital amidst commercial launch costs.